State Ledger
Company profile

Kalaris Therapeutics, Inc. CIK 1754068

Ticker
KLRS (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Berkeley Heights, NJ 07922
Fiscal year end
2025 (FY)
Market Data
Close
$2.24
Change
-$0.02
Change %
-0.67%
Volume
2,311

KLRS · trading date Oct 13, 2026 · previous close $2.26 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$43.44M
Total assets
$121.74M
Total liabilities
$42.92M
Stockholders' equity
$78.81M
Cash & equivalents
$98.05M
Operating income
-$46.15M
Operating cash flow
-$38.37M
Capital expenditures
$200.0K

Fiscal year 2025, via 10-K filed 2026-03-17. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$38.57M
Free cash flow margin
—
Liabilities / assets
35.3%
Equity / assets
64.7%
CapEx / revenue
—
Operating cash flow / net income
0.88×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$43.44M $121.74M $42.92M $78.81M
2024 — -$69.17M $6.16M $56.78M -$96.62M
2023 — -$190.42M $190.80M $45.02M -$45.02M
2022 — -$168.71M $277.08M $52.56M $224.52M
2021 — -$171.96M $286.59M $61.33M $225.27M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-08-28
Financials filed via
Form 10-K
filed 2026-03-17

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Berkeley Heights, NJ 07922
400 CONNELL DRIVE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:40 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New Jersey — Public Companies